What Changed in March and Why It Matters for Your Arteries

The 2026 ACC/AHA lipid guidelines just rewrote the rules on cholesterol management. Here is what they say and where imaging fits in.

In March 2026, the ACC and AHA finally replaced their 2018 lipid guidelines, and the new framework is a real step forward. It brings back specific LDL targets, elevates the importance of advanced biomarkers like ApoB and Lp(a), and gives imaging a much clearer role in deciding who actually needs aggressive treatment.

The overall direction of the medical community is finally catching up to what prevention-focused physicians have been saying for years: identify risk earlier, treat it earlier, and stop pretending a basic lipid panel tells the whole story. But did they go far enough?

The return of hard targets

The most important change is the return of specific LDL goals. Under the old rules, the approach was often vague. The medical system became too comfortable just putting a patient on a statin and hoping for the best, without focusing enough on where the numbers actually ended up.

That era is over. The new targets are clear: under 70 mg/dL for intermediate-risk primary prevention, and under 55 mg/dL for higher-risk patients or those with established cardiovascular disease.

The logic behind this comes down to how heart disease actually develops. Atherosclerosis is cumulative. Your LDL doesn't magically become dangerous the day you turn fifty. It contributes to plaque buildup over decades. Mendelian randomization studies have shown that for every 1 mmol/L reduction in LDL sustained from young adulthood, the lifetime reduction in major cardiovascular events is roughly three times greater than the same reduction started in middle age. Duration matters just as much as magnitude. Lowering your LDL at age 35 is fundamentally different than lowering it at age 55, even if you eventually hit the exact same LDL number.

This also means the real question is no longer just whether you're on a statin. The question is whether your medication is actually pushing your risk down to a safe level. If statins aren't enough, the new guidelines are much more open to combination therapies like ezetimibe, bempedoic acid, and PCSK9 inhibitors.

Exposing the blind spots: ApoB and Lp(a)

The update also gives major weight to biomarkers that expose the limitations of standard cholesterol tests.

I regularly see patients who have an LDL that doesn't look especially alarming, but when we check their ApoB, the picture becomes more complete. ApoB reflects the actual number of atherogenic particles in your blood, not just the total mass of cholesterol inside them. You can have a normal cholesterol level but a dangerously high number of particles driving plaque into your artery walls. This is common in patients with insulin resistance, metabolic syndrome, or elevated triglycerides. If the biology we care about is driven by particle number, measuring cholesterol mass alone has been an incomplete strategy.

Then there's lipoprotein(a), or Lp(a). It's a genetic, pro-atherogenic biomarker that most patients have never even heard of. It isn't on a routine lipid panel, which is hard to justify now that the guidelines recommend measuring it in every adult. The usual objection from traditional medicine is that we don't yet have a widely approved drug to lower it directly. But that completely misses the point. We don't measure Lp(a) just to treat the Lp(a). We measure it because if you're carrying a high inherited risk, it completely changes how aggressively we need to manage everything else we can control, like blood pressure, LDL, and exercise.

When theory meets reality: imaging

A coronary artery calcium score remains one of the best ways to refine your risk when standard calculators fall short. It's quick, inexpensive, and gives direct evidence of calcified plaque burden. A score of zero can be reassuring and might suggest that immediate pharmaceutical intervention isn't urgent. But a high score does the exact opposite. It tells you the disease process is already underway, regardless of how comfortable your bloodwork looked.

A CCTA goes a step further because it can detect soft, non-calcified plaque. This is a vital distinction. Some patients have a zero calcium score but are absolutely not plaque-free. Soft plaque is often the kind that ruptures and causes a cardiac event. CCTA isn't a mass screening tool, but in the right patient it answers questions that bloodwork and calcium scoring simply can't settle.

Each of these tools builds on the one before it. A standard lipid panel tells you how much cholesterol is in your blood. ApoB tells you how many atherogenic particles you're carrying. Lp(a) tells you whether your genetics are stacking the deck. A calcium score tells you how much of it has already turned into disease. A CCTA tells you what kind of disease it is. No single test tells the full story.

So did they go far enough?

It's a start. The targets are lower, the biomarkers are broader, and the role of imaging is clearer. But some experts argue the new targets are still conservative. In the FOURIER trial, patients who achieved an LDL around 30 mg/dL showed progressively fewer cardiovascular events with no observed lower threshold of benefit. The GLAGOV trial showed actual plaque regression on intravascular ultrasound at a mean LDL of 37 mg/dL. Whether that level of aggression is appropriate depends on the individual patient, their risk profile, their tolerance for therapy, and how much disease has already accumulated.

A basic lipid panel was never enough. These guidelines finally acknowledge that. But like all questions in medicine, the right target for you is a conversation between you and a physician who understands your current biology and trajectory, not a number pulled from a table.